Author:
Bian Yanqin,Chen Xi,Cao Hongyan,Xie Dong,Zhu Meiping,Yuan Nong,Lu Lu,Lu Bingjie,Wu Chao,Bahaji Azami Nisma Lena,Wang Zheng,Wang Huijun,Zhang Yeqing,Li Kun,Ye Guan,Sun Mingyu
Abstract
Abstract
Background
Weifuchun (WFC), a Chinese herbal prescription consisting of Red Ginseng, Isodon amethystoides and Fructus Aurantii, is commonly used in China to treat a variety of chronic stomach disorders. The aim of the paper was to determine the effect of WFC on intestinal microbiota changes in precancerous lesions of gastric cancer (PLGC) patients.
Methods
PLGC patients of H. pylori negative were randomly divided into two groups and received either WFC tablets for a dose of 1.44 g three times a day or vitacoenzyme (Vit) tablets for a dose of 0.8 g three times a day. All patients were treated for 6 months consecutively. Gastroscopy and histopathology were used to assess the histopathological changes in gastric tissues before and after treatment. 16S rRNA gene sequencing was carried out to assess the effects WFC on intestinal microbiota changes in PLGC patients. Receiver Operating Characteristics (ROC) analysis was used to assess the sensitivity and specificity of different intestinal microbiota in distinguishing between PLGC patients and healthy control group.
Results
Gastroscopy and histopathological results indicated that WFC could improve the pathological condition of PLGC patients, especially in the case of atrophy or intestinal metaplasia. The results of 16S rRNA gene sequencing indicated that WFC could regulate microbial diversity, microbial composition, and abundance of the intestinal microbiota of PLGC patients. Following WFC treatment, the relative abundance of Parabacteroides decreased in WFC group when compared with the Vit group. ROC analysis found that the Parabacteroides could effectively distinguish PLGC patients from healthy individuals with sensitivity of 0.79 and specificity of 0.8.
Conclusions
WFC could slow down the progression of PLGC by regulating intestinal microbiota abundance.
Trial registration NCT03814629. Name of registry: Randomized Clinical Trial: Weifuchun Treatment on Precancerous Lesions of Gastric Cancer. Registered 3 August 2018-Retrospectively registered, https://register.clinicaltrials.gov/ NCT03814629.
Funder
Science and Technology Commission of Shanghai Municipality
State Administration of Traditional Chinese Medicine of the People's Republic of China
Collaborative Innovation Center for Modern Science and Technology and Industrial Development of Jiangxi Traditional Medicine
Shanghai University of Traditional Chinese Medicine
Key Disciplines of Liver and Gall Bladder Diseases and Key Laboratory of Chronic Deficiency Liver Disease of State Administration of Traditional Chinese Medicine of the People’s Republic of China
Publisher
Springer Science and Business Media LLC
Subject
Complementary and alternative medicine,Pharmacology
Reference58 articles.
1. Torre LA, Bray F, Siegel RL, et al. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65(2):87–108.
2. Wang W, Sun Z, Deng JY, et al. A novel nomogram individually predicting disease-specific survival after D2 gastrectomy for advanced gastric cancer. Cancer Commun (Lond). 2018;38(1):23.
3. Chen J, Domingue JC, Sears CL. Microbiota dysbiosis in select human cancers: evidence of association and causality. Semin Immunol. 2017;32:25–34.
4. Wong SH, Kwong T, Wu CY, et al. Clinical applications of gut microbiota in cancer biology. Semin Cancer Biol. 2019;55:28–36.
5. Zhang J, Wang H. Morroniside protects against chronic atrophic gastritis in rat via inhibiting inflammation and apoptosis. Am J Transl Res. 2019;11(9):6016–23.
Cited by
13 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献